Introduction

Heparin-induced thrombocytopenia (HIT) is a potentially serious immune-mediated adverse reaction that can occur as a result of using heparin, which is a commonly used anticoagulant medication. End-stage renal disease (ESRD) patients, especially those on dialysis, are at higher risk due to frequent exposure to heparin. HIT can be classified into two types: type I, characterised by non-immune-mediated platelet aggregation and mild thrombocytopenia, and type II, involving immune-mediated platelet activation and consumption. Heparin binds to platelet factor 4 (PF4), triggering the production of heparin-PF4 antibodies that activate platelets, leading to widespread platelet consumption, hypercoagulability, and thrombosis.

A comprehensive search of the PubMed, Embase, and Cochrane Library databases was performed from inception to December 2022 to identify relevant articles in order to conduct a review article on the topic.

The prevalence of HIT in ESRD patients is not well established due to limited data. However, studies suggest that ESRD patients may have an increased risk of HIT due to underlying medical conditions and heparin exposure during hemodialysis (HD). One study reported a 4.6% HIT prevalence rate in ESRD patients receiving ultra-fractionated heparin during hospitalisation. The exact prevalence of HIT in ESRD patients remains unclear, varying based on heparin type, patient comorbidities, and individual risk factors. Healthcare providers should be aware of the potential risk and monitor for signs and symptoms of HIT during heparin treatment.

The specific mechanism of heparin-induced thrombocytopenia (HIT) in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) is not fully understood.

HIT is an immune-mediated drug reaction where heparin binds to platelet factor 4 (PF4), triggering the production of antibodies that activate platelets and lead to thrombocytopenia. The presence of ESRD and heparin exposure during HD may contribute to an increased risk of developing HIT.

Heparin-induced thrombocytopenia (HIT) can occur at any point during the administration of heparin, regardless of whether it is given at the beginning of treatment or after a long period of hemodialysis (HD). Some studies suggest that the risk of developing HIT may be higher in the first few weeks of heparin exposure, especially in patients with no prior heparin exposure.

The use of heparin or heparin-like coated HD membranes may slightly increase the risk of HIT as these membranes can release small amounts of heparin during use. The overall risk of developing heparin-induced thrombocytopenia (HIT) with the use of membranes, such as hemodialysis or membrane oxygenators, is considered relatively low. Non-heparin anticoagulants like citrate have been proposed as safer alternatives in high-risk patients.

Further research is needed to fully understand the pathogenesis of HIT in ESRD patients undergoing HD and to explore alternative anticoagulation strategies, particularly in patients at high risk for HIT.

Etiologies

The use of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) is common in end-stage renal disease (ESRD) patients, particularly those undergoing hemodialysis (HD). UFH is preferred over LMWH due to its lower cost, ease of use, rapid half-life, and lower risk of bleeding. Studies comparing both agents in ESRD patients have shown similar bleeding safety profiles, but the risk of developing clinical heparin-induced thrombocytopenia (HIT) with these agents in this population is not well-established.

Temporality

ESRD patients on HD who receive unfractionated heparin have shown a temporal pattern of heparin-induced antibodies (HIA) production. While positive HIA may not be significantly associated with the risk of thrombocytopenia or thrombosis, subsequent thrombotic events occur more frequently in patients with strong positive HIA. This suggests the need for further research to explore the relationship between HIA and the risk of thrombosis in this population.

Morbidity

HIT can result in various adverse effects, including bleeding, thrombocytopenia, thrombosis, increased healthcare costs, and prolonged hospitalisation. Previous research has suggested that HIA in dialysis patients with ESRD may increase the risk of clinical thrombosis. However, recent studies have not found a significant association between HIA results and thrombotic events, vascular access thrombosis, bleeding, or thrombocytopenia.

Mortality

Studies have shown that a positive test for HIA is associated with higher mortality rates in ESRD patients, particularly in those with higher titers of HIA. However, the impact of HIT on mortality requires further investigation. It is worth noting that the diagnosis of HIT in these studies did not employ a functional assay, which may have led to an underestimation of the population under study.

When to Suspect HIT

HIT should be suspected when a patient develops thrombocytopenia or manifests clinical evidence of thrombosis. It typically occurs within 5 to 14 days after the initiation of heparin. The 4T score is commonly used to assess the pre-test probability of HIT, but its application in the ESRD population may result in overdiagnosis. The HEP score has been evaluated in HD patients and may be a more reliable screening tool with a higher negative predictive value for HIT.

Laboratory Diagnosis

The enzyme immunoassay (EIA) for detecting PF4/heparin is the most commonly used laboratory marker for HIT diagnosis. A positive result does not rule in the diagnosis, and higher optical density (OD) values (>1.0) may be associated with a more accurate diagnosis of HIT. However, different OD thresholds and sensitivities may vary among studies and assays. The presence of HIA does not correlate with the incidence of thrombocytopenia in ESRD patients, highlighting the challenges in using EIA as a diagnostic tool for HIT in this population.

Functional Assays

Functional assays, such as the serotonin-releasing assay (SRA) and heparin-induced platelet activation (HIPA) assay, are used to detect platelet-activating HIA. The SRA is highly specific but not practical for routine diagnosis. The relative sensitivity, specificity, and accuracy of functional assays in ESRD patients have not been well-studied. SRA-negative HIT has been reported, emphasizing the importance of clinical suspicion even when gold standard laboratory testing is negative.

Treatment:

The management of heparin-induced thrombocytopenia (HIT) focuses on two main objectives: stopping platelet activation and providing therapeutic anticoagulation with non-heparin products. Discontinuing all heparin products immediately is crucial to prevent further platelet activation. Guidelines recommend the use of argatroban or danaparoid as non-heparin anticoagulants, while regional citrate is suggested for patients with a history of HIT requiring ongoing renal replacement therapy or catheter locking. However, there have been no head-to-head studies comparing the efficacy and safety of non-heparin anticoagulants in HIT patients on renal replacement therapy. Argatroban is the only medication approved by the FDA for HIT treatment. It inhibits thrombin directly and is safe to use in patients with chronic kidney disease and end-stage renal disease (ESRD) on hemodialysis (HD). Bivalirudin, lepirudin, danaparoid, and fondaparinux are other non-heparin alternatives with varying pharmacokinetics and dosing considerations. Direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, and apixaban have shown promise as safer alternatives for HIT treatment, including in ESRD patients on HD. Vitamin K antagonists may be resumed during the subacute phase of HIT but should be overlapped with a non-heparin anticoagulant. Nucleic acid aptamers and lipoxygenase-inhibition are emerging treatment options, although further research is needed. The choice of non-heparin anticoagulant should consider the patient's renal function, bleeding risk, and individual factors. While evidence is limited for some alternatives, the American Society of Hematology (ASH) has included DOACs as potential treatment options for HIT. Continued research is required to optimise HIT management and determine the safety and efficacy of these treatments in patients with kidney dysfunction or undergoing HD. Overall, the etiology and diagnosis of HIT in ESRD patients on HD present unique challenges. The choice of heparin agents, the temporal pattern of HIA production, the association with morbidity and mortality, and the limitations of diagnostic tools in this population require further investigation.

References:

- Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med. 2020;25(2):160-173. doi: 10.1177/1358863(19898253).
- Pollak U. Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: review of the literature and alternative anticoagulants. J Thromb Haemost. 2019;17(10):1608-1622. doi: 10.1111/jth.14575 . 
- Suranyi M, Chow JS. Review: anticoagulation for haemodialysis. Nephrology (Carlton). 2010;15(4):386-392. doi: 10.1111/j.1440-1797.2010.01298.
- Lazrak HH, René É, Elftouh N, et al. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):187. doi: 10.1186/s12882-017-0596-4
- Maharaj S, Chang S, Seegobin K, et al. Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol. 2018;7(23). doi: 10.1186/s40164-018-0115-8
- Cuker A, Arepally G, Crowther MA, et al. The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642-2650. doi: 10.1111/j.1538-7836.2010.04059.
- Alberio L. Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment. Curr Opin Hematol. 2008;15(5):456-464. doi: 10.1097/MOH.0b013e32830b84a2 
- Barlow A, Barlow B, Reinaker T, et al. Potential role of direct oral anticoagulants in the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2019;39(8):837-853. doi: 10.1002/phar.2298
- Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):340s–380 s. doi: 10.1378/chest.08-0677